Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Spain: Anticude; UK: Edrophonium.

North America

Canada: Tensilon; USA: Edrophonium, Enlon, Tensilon.


Japan: Antirex.

Drug combinations

Edrophonium and Atropine


Edrophonium Chloride: C~10~H~16~ClNO. Mw: 201.69. (1) Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl-, chloride; (2) Ethyl(m-hydroxyphenyl)dimethylammonium chloride. CAS-116-38-1; CAS-312-48-1 (edrophonium).

Pharmacologic Category

Diagnostic Agents; Myasthenia Gravis; Cholinergic Agonist. Antidotes. (ATC-Code: N07AA).

Mechanism of action

A synthetic quaternary ammonium parasympathomimetic (cholinergic) agent, used to diagnose myasthenia gravis. Inhibits destruction of acetylcholine by acetylcholinesterase, facilitating transmission of impulses across myoneural junction and increasing cholinergic responses such as miosis, increased tonus of intestinal and skeletal muscles, bronchial and ureteral constriction, bradycardia, and increased salivary and sweat gland secretions.

Therapeutic use

Differential diagnosis of myasthenia gravis. May also be used to differentiate cholinergic crisis from myasthenic crisis. Reversal of nondepolarizing neuromuscular blockers. Respiratory depression caused by curare overdose.

Pregnancy and lactiation implications

Anticholinesterase drugs may cause uterine irritability and induce premature labor when given I.V. to pregnant women near term. Use of edrophonium in pregnant women requires possible benefits to be weighed against potential risks. Safe use of edrophonium in nursing women not established.

Unlabeled use


Hypersensitivity to edrophonium, sulfites, or any component of the formulation. GI or GU obstruction.

Warnings and precautions

Overdosage can cause potentially fatal cholinergic crisis. Use with caution in cardiac arrhythmias (e.g. bradyarrhythmias). Should be used cautiously in bronchial asthma and in patients receiving a cardiac glycoside (may enhance AV block). Avoid use in myasthenia gravis (may exacerbate muscular weakness). Products may contain sodium sulfite (may cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in certain susceptible individuals.). Edrophonium is contraindicated in mechanical obstruction of the intestinal or urinary tracts.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart